Advanced Colorectal Cancer Clinical Trial
Official title:
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
The primary objective is to assess the antitumor activity of the treatment combinations based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary Objectives: 1. Assess impact of treatment combinations on survival 2. Characterize the safety profile of the treatment combinations (DLTs) 3. Evaluate the pharmacodynamics of the avutometinib combination with defactinib plus cetuximab. 4. Evaluate for pERK and Ki67 inhibition Exploratory Objectives - Assess blood- and tissue-based predictive biomarkers of activity upon treatment with cetuximab plus avutometinib plus defactinib - Demonstrate feasibility of establishing patient-derived xenograft (PDX) models in matched patients with cetuximab-refractory mCRC to evaluate for biomarkers of response and mechanisms of resistance. - Explore mechanisms of resistance to cetuximab plus avutometinib and defactinib ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05028933 -
IMC001 for Clinical Research on Advanced Digestive System Malignancies
|
Phase 1 | |
| Recruiting |
NCT06200363 -
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT02923622 -
Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
|
N/A | |
| Completed |
NCT01723969 -
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
|
||
| Active, not recruiting |
NCT00309179 -
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03699111 -
Identification of New Patient Stratification Tools in MSS RAS mt mCRC
|
||
| Not yet recruiting |
NCT02826837 -
LEAC-102 for Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05077839 -
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
|
Phase 2 | |
| Recruiting |
NCT04324476 -
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT01271166 -
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00386828 -
Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
|
Phase 2 | |
| Recruiting |
NCT04764006 -
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
|
Phase 2 | |
| Active, not recruiting |
NCT04835324 -
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
|
||
| Active, not recruiting |
NCT02619435 -
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT01822444 -
ANGIOPREDICT. ICORG 12-16, V3
|
||
| Completed |
NCT00498407 -
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05731336 -
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
|
||
| Active, not recruiting |
NCT04744831 -
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT03311750 -
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
|
Phase 2 |